How much funding has Hepta Bio raised?

Hepta Bio has raised $6.7M in total funding, most recently a Seed round.

Where is Hepta Bio headquartered?

Hepta Bio is headquartered in San Francisco, California, United States.

What industry is Hepta Bio in?

Hepta Bio operates in Artificial Intelligence, Biotech, Healthcare.

Hepta Bio

Q: Who are Hepta Bio's investors?

Hepta Bio's investors include Felicis Ventures, Illumina Ventures, Alumni Ventures.

Liquid biopsy, built for chronic disease

San Francisco, United States · Founded 2025 · $6.7M raised

Artificial Intelligence

Biotech

Healthcare

Headquarters: San Francisco, California
Employees: 1–10
Founded: 2025
Business Model: B2B

Total Funding: $6.7M
Last Round: $6.7M SeedNov 2025
Rounds: 1

About

Hepta Bio is an AI-powered liquid biopsy company decoding tissue-level biology from blood, with a focus on metabolic dysfunction-associated steatohepatitis (MASH) and chronic liver disease. The company's LiquidTransformer platform — the first liquid biopsy-native AI — uses patented transformer-based models to read epigenetic patterns in cell-free DNA at single-molecule resolution, enabling non-invasive diagnosis and therapy response monitoring for the approximately 20 million Americans living with MASH. Backed by Felicis Ventures, Illumina Ventures, SeaX Ventures, AME Cloud Ventures, and Alumni Ventures, Hepta was founded in 2025 by Illumina and GRAIL veterans and has presented at AASLD, EASL, and DDW.

Summary

Hepta Bio is an Artificial Intelligence company based in San Francisco, United States, founded in 2025. It has raised $6.7M in total across 1 round, most recently a $6.7M Seed round in Nov 2025. Investors include Felicis Ventures, Illumina Ventures and Alumni Ventures.